Table 4.
Effect of Infant’s Age on Validated DEG in Infants with AD
| DEG | Group | LFC | FC | FDR |
|---|---|---|---|---|
| IL18RAP | Patients with AD aged >6 mo versus HCs | ‒1.968 | 0.256 | 0.003 |
| Patients with AD aged <6 mo versus HCs | ‒1.309 | 0.404 | 0.043 | |
| IL1B | Patients with AD aged <6 mo versus HCs | 3.901 | 14.942 | 0.000 |
| TNF | Patients with AD aged <6 mo versus HCs | 3.092 | 8.526 | 0.000 |
| TREM1 | Patients with AD aged <6 mo versus HCs | 3.164 | 8.963 | 0.000 |
| EGR3 | Patients with AD aged <6 mo versus HCs | 5.076 | 33.732 | 0.015 |
Shown is the effect of infant’s age on the expression of selected genes that were differentially expressed in infants with AD and validated by RT-qPCR. Differential expression analysis between patients with AD and HCs was performed using DESeq2 on RNA-seq data after stratifying the dataset by age (0‒6 months and 7‒12 months).
Abbreviations: AD, atopic dermatitis; AIF, apoptosis-inducing factor; DEG, differentially expressed gene; FC, fold change; FDR, false discovery rate; HC, healthy control; LFC, log2 fold change; OSM, oncostatin M; RNA-seq, RNA sequencing; XAF1, XIAP-associated factor 1.